Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Mölnlycke establishes first wound care manufacturing site in China
Changshu, China, and Gothenburg, Sweden. 5 November 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu, China. This strategic investment marks a milestone in Mölnlycke’s growth journey and the beginning of localised manufacturing in one of the world’s fastest-growing MedTech markets.
“Our site in Changshu marks another step forward in Mölnlycke’s ambition to manufacture products closer to where they are sold. It reflects our glocal approach, combining global standards with local relevance, and reinforces our commitment to sustainable growth, supply chain resilience and faster delivery of life-changing wound care solutions to caregivers and patients in China,” says Zlatko Rihter, CEO of Mölnlycke.
The manufacturing site, spanning 10,000 m2, will be set up in accordance with Mölnlycke’s global standards and is expected to initiate production of Mölnlycke wound care products at the end of 2026/early 2027. This strategic move will help future-proof Mölnlycke’s growth in China, laying the foundation for future capacity expansion and local job creation.
“This investment brings us closer to our customers in China and reinforces our mission to free patients and caregivers from the burden of wounds, with locally produced, high-quality solutions,” adds Jakob Sonnenberg, VP Greater China & India Wound Care at Mölnlycke.
The Changshu site strengthens Mölnlycke’s position in Asia and aligns with China’s growing demand for advanced, locally manufactured healthcare solutions.
For more information, please contact:
Latest news
Read all news-
5 million and growing: scaling Granudacyn® production in Salzburg
-
First factory in China reaches key milestone and strengthens Mölnlycke’s global manufacturing network
Mölnlycke has completed construction of its first manufacturing facility in China, marking a major milestone in the company's growth journey and strengthening its ability to serve one of the world's largest and fastest growing healthcare markets.
-
Mölnlycke Health Care accelerates U.S. growth journey with three wound care product launches
Peachtree Corners, GA. 7 July, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
-
Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care
Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.
-
Mölnlycke Health Care and Zhende Medical form pioneering joint venture to expand access to advanced wound care solutions in China
Gothenburg, Sweden, and Shanghai, China. 21 May 2026.
Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech and advanced wound care solutions, and Zhende Medical, a leading supplier of medical care and protection in China, today announce the formation of a new joint venture company in China to accelerate growth in one of the world’s fastest-growing wound care markets. The joint venture, majority-owned by Mölnlycke, will integrate the two companies’ wound care portfolios and commercial capabilities to offer healthcare providers, patients and the public expanded access to advanced treatments, improved care delivery and better patient outcomes across China. -
Simple glove change could save the NHS £45 million over five years and improve caesarean safety
Gothenburg, Sweden. 27 April 2026. A new study1 published in the Journal of Hospital Infection shows that introducing a simple glove change during caesarean birth could deliver millions in cost savings for the National Health Service (NHS) in England.
-
Mölnlycke Health Care announces Andreas Johansson as Interim Chief Financial Officer
Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect.
-
Mölnlycke Health Care annual report 2025 highlights sustainable growth and strategic transformation
Gothenburg, Sweden. 1 April 2026. Today, Mölnlycke Health Care has published its annual report 2025, including sustainability report, outlining the company’s continued focus on revolutionising care for people and planet.